Janux Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a JANX research report →
Companywww.januxrx.com
Janux Therapeutics, Inc. , a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.
- CEO
- David Alan Campbell
- IPO
- 2021
- Employees
- 91
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $878.17M
- P/E
- -7.88
- P/S
- 40.63
- P/B
- 0.96
- EV/EBITDA
- -6.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 54.15%
- Op Margin
- -726.34%
- Net Margin
- -529.67%
- ROE
- -11.85%
- ROIC
- -16.15%
Growth & Income
- Revenue
- $10.00M · -5.55%
- Net Income
- $-113,625,000 · -64.69%
- EPS
- $-1.83 · -42.97%
- Op Income
- $-157,667,000
- FCF YoY
- -88.53%
Performance & Tape
- 52W High
- $35.34
- 52W Low
- $12.12
- 50D MA
- $14.42
- 200D MA
- $19.09
- Beta
- 2.57
- Avg Volume
- 1.05M
Get TickerSpark's AI analysis on JANX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 11, 26 | Dobek Maria | sell | 2,038 |
| Feb 2, 26 | Go William | other | 154,000 |
| Feb 2, 26 | Go William | other | 44,000 |
| Jan 26, 26 | Go William | other | 0 |
| Jan 2, 26 | Meyer Andrew Hollman | sell | 1,879 |
| Jan 2, 26 | DiRaimondo Thomas | other | 31,400 |
| Jan 2, 26 | DiRaimondo Thomas | sell | 2,505 |
| Jan 2, 26 | DiRaimondo Thomas | other | 109,900 |
| Jan 2, 26 | Campbell David Alan | other | 96,600 |
| Jan 2, 26 | Campbell David Alan | other | 338,100 |
Our JANX Coverage
We haven't published any research on JANX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate JANX Report →